抗粉样蛋白疗法,AD和ARIA:解开CAA的作用
Mo-Kyung Sin1, Edward Zamrini2, Ali Ahmed3
1College of Nursing, Seattle University, Seattle, WA 98122, USA.
Journal of clinical medicine
|November 14, 2023
概括
针对阿尔茨海默病 (AD) 的新兴抗粉样蛋白疗法增加了ARIA的风险. 识别脑粉样血管病变 (CAA) 对于管理这些风险至关重要.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 放射学 放射学是一门学科.
背景情况:
- 抗粉样蛋白疗法 (AATs) 在早期阿尔茨海默病 (AD) 中准粉样蛋白斑块.
- 与粉样蛋白相关的成像异常 (ARIA) 是AATs的一种副作用,与大脑粉样蛋白血管病变 (CAA) 有关.
- 了解ARIA病理生理学是早期风险检测和分层的关键.
研究的目的:
- 强调需要改进的生物标志物来检测和评估脑粉样血管病变 (CAA) 的严重程度.
- 突出识别具有ARIA并发症高风险的个体的重要性.
- 在接受抗粉胺治疗的患者中减少症状性ARIA.
主要方法:
- 审查与AD和CAA相关的ARIA病理生理学的当前理解.
- 讨论CAA. 遗传病理学确认的局限性.
- 评估体内工具,如MRI和现有的生物标志物 (CSF Aβ,粉样PET) 用于CAA检测.
主要成果:
- 大脑粉样蛋白血管病变 (CAA) 是接受抗粉样蛋白治疗的患者ARIA的一个显著风险因素.
- 目前的生物标志物缺乏特异性来区分CAA与AD粉样斑块.
- 核磁共振是检测CAA的可行的体内工具,但需要进一步开发生物标志物.
结论:
- 准确和敏感的CAA生物标志物是最大限度地减少ARIA并发症的优先事项.
- 改善ARIA风险分层对于安全有效的AAT管理至关重要.
- 为了临床应用,需要对CAA的新生物标志物进行进一步的研究.
更多相关视频
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
9.3K
10:36In Vitro Assays to Assess Blood-brain Barrier Mesh-like Vessel Formation and Disruption
Published on: June 20, 2017
8.5K
相关概念视频
Alzheimer's Disease: Treatment
197
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
197
Alzheimer's Disease: Overview
498
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
498
Aneurysm III: Interprofessional Care
9
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
9
Peripheral Artery Disease III: Interprofessional Care
11
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
11
Atherosclerosis III: Management
11
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
11
Parkinson's Disease: Treatment
281
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
281
